Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

White House Withdraws Overton’s FDA Nomination

Published 18 November 2026 · All stories from this day

The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration on November 17, a day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on advancing her nomination. The decision leaves the FDA under acting leadership while the administration considers possible replacements.

A senior administration official said Overton lacked sufficient support on Capitol Hill to move forward. The White House did not publicly provide a vote count. Republicans held a one-seat advantage on the committee, where a single Republican defection could have blocked the nomination if all Democrats opposed it.

Sen. Bill Cassidy, the committee’s Republican chairman, disputed the administration’s assessment. He said he believed Overton had a viable path and enough votes to pass both the committee and the full Senate, citing productive conversations with members. The competing assessments leave the decisive reason for the withdrawal unsettled.

Cassidy had raised concerns about Overton’s management experience and her role in the administration’s efforts to change childhood vaccine recommendations. At her September confirmation hearing, he...

Now playing
0:00 / 0:00